126 related articles for article (PubMed ID: 38753328)
1. Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.
Lamba JK; Marrero R; Wu H; Cao X; Parcha PK; Karol SE; Inaba H; Kuo DJ; Degar BA; Heym K; Taub JW; Lacayo NJ; Pui CH; Ribeiro RC; Pounds SB; Rubnitz JE
JAMA Netw Open; 2024 May; 7(5):e2411726. PubMed ID: 38753328
[TBL] [Abstract][Full Text] [Related]
2. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
5. Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience.
Rubnitz JE; Lensing S; Razzouk BI; Pounds S; Pui CH; Ribeiro RC
Pediatr Blood Cancer; 2007 Jan; 48(1):10-5. PubMed ID: 16642489
[TBL] [Abstract][Full Text] [Related]
6. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
[TBL] [Abstract][Full Text] [Related]
7. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
9. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Gupta N; Miller A; Gandhi S; Ford LA; Vigil CE; Griffiths EA; Thompson JE; Wetzler M; Wang ES
Am J Hematol; 2015 Jul; 90(7):639-46. PubMed ID: 25808347
[TBL] [Abstract][Full Text] [Related]
10. Results of therapy for acute lymphoblastic leukemia in black and white children.
Pui CH; Sandlund JT; Pei D; Rivera GK; Howard SC; Ribeiro RC; Rubnitz JE; Razzouk BI; Hudson MM; Cheng C; Raimondi SC; Behm FG; Downing JR; Relling MV; Evans WE
JAMA; 2003 Oct; 290(15):2001-7. PubMed ID: 14559953
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
12. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
Kahn JM; Keegan TH; Tao L; Abrahão R; Bleyer A; Viny AD
Cancer; 2016 Sep; 122(17):2723-30. PubMed ID: 27286322
[TBL] [Abstract][Full Text] [Related]
13. Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia.
Li Y; Newton JG; Getz KD; Huang YS; Seif AE; Fisher BT; Aplenc R; Winestone LE
Pediatr Blood Cancer; 2019 Apr; 66(4):e27583. PubMed ID: 30585685
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
15. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.
Winestone LE; Getz KD; Miller TP; Wilkes JJ; Sack L; Li Y; Huang YS; Seif AE; Bagatell R; Fisher BT; Epstein AJ; Aplenc R
Am J Hematol; 2017 Feb; 92(2):141-148. PubMed ID: 27862214
[TBL] [Abstract][Full Text] [Related]
16. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
[TBL] [Abstract][Full Text] [Related]
19. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
20. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Vekemans MC; Biemond B; Sonneveld P; Passweg J; Verdonck L; Legdeur MC; Theobald M; Jacky E; Bargetzi M; Maertens J; Ossenkoppele GJ; Löwenberg B; ; ;
Blood; 2012 Jun; 119(23):5367-73. PubMed ID: 22422824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
